This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Lung crisis in sickle cell anaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Sickle cell crises in the lung - otherwise referred to as acute chest syndrome (ACS) - are characterised by pleuritic chest pains, fever, abnormal chest examinations and presence of new infiltrations in the chest X ray (1).

  • is the second most common cause of hospital admission in SCD patients (2)
  • around half of all SCD patients will experience at least one episode of ACS during their lives (3)
  • in some areas, the acute chest syndrome is the commonest cause of death in sickle cell anaemia.

They are of mixed pathology; caused by a combination of infection, fat embolism and vaso occlusion of the pulmonary vasculature (2)

  • mostly seen during early childhood (usually presents with clinical features that are more typical for pneumonia)
  • in later childhood and adulthood, it is more frequent during a painful crises or after anaesthesia (1)

A combination of clinical signs or symptoms of chest consolidation and worsening hypoxia is sufficient for the diagnosis of ACS (since X ray changes often lag behind clinical signs) (3)

Local protocols should be prepared for management of ACS and should include:

  • analgesia
  • monitoring arterial blood gas measurement
  • oxygen and respiratory support - persistent, profound hypoxia is an indication for ventilation.
  • incentive spirometry – useful in SCD patients presenting with chest or back pain above the diaphragm to prevent pulmonary complications
  • fluid management
  • bronchodilator therapy – for patients with evidence of wheeze or reversible airways disease, or a history of asthma
  • antibiotic treatment may be indicated
  • blood transfusion (3)

Longterm treatment with hydroxycarbamide (former British Approved Name, hydroxyurea) has led to a reduction by 50% in acute chest syndrome in some studies.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.